Keyphrases
Acute Leukemia
23%
Acute Lymphoblastic Leukemia
11%
Acute Myeloid Leukemia
36%
Adoptive Immunotherapy
12%
Allogeneic
11%
Allogeneic Bone Marrow Transplantation
45%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
72%
Antileukemic Activity
11%
Bone Marrow
27%
Bone Marrow Transplantation
82%
Canine
28%
Chemotherapy
15%
Chimera
10%
Chimerism
13%
Chronic Myeloid Leukemia
79%
Chronic Phase
11%
Complete Remission
10%
Cyclophosphamide
12%
Dendritic Cells
21%
Donor Lymphocyte Infusion
25%
Engraftment
13%
Graft-versus-host Disease (GvHD)
100%
Graft-versus-leukemia Effect
18%
Hematopoietic Stem Cell Transplantation
25%
Hematopoietic Stem Cells
14%
High Risk
13%
HLA-identical Sibling
14%
Hydroxyurea
12%
Interferon-α (IFN-α)
23%
Leukemia
40%
Leukemia Patients
12%
Leukemia-derived Dendritic Cells
10%
Leukocytes
9%
Marrow
42%
Marrow Transplantation
23%
Myelodysplastic Syndrome
18%
Overall Survival
15%
Reduced-intensity Conditioning
11%
Remission
11%
Risk Factors
10%
Stem Cell Transplantation
20%
Stem Cells
11%
T Cells
32%
Total Body Irradiation
15%
Transfusion
12%
Transplant-related Mortality
13%
Transplantation
48%
Unrelated Donor
16%
Venous Disease
11%
Working Party
16%
Medicine and Dentistry
Acute Graft Versus Host Disease
11%
Acute Leukemia
23%
Acute Lymphoblastic Leukemia
10%
Acute Myelogenous Leukemia
12%
Acute Myeloid Leukemia
35%
Adoptive Immunotherapy
10%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Allogeneic Stem Cell Transplantation
36%
Allogenic Bone Marrow Transplantation
28%
Allograft
12%
Aplastic Anemia
6%
Bone Marrow Cell
6%
Bone Marrow Transplantation
72%
Cancer
8%
Chronic Graft Versus Host Disease
12%
Chronic Myelogenous Leukemia
57%
Chronic Myelogenous Leukemia
6%
Conditioning
19%
Cyclosporine
7%
Cytarabine
6%
Cytokine
6%
Dendritic Cell
18%
Diseases
39%
Donor Lymphocyte Infusion
10%
Engraftment
6%
Globulin
6%
Graft Versus Host Reaction
46%
Graft Versus Leukemia Effect
15%
Hematologic Malignancy
6%
Hematopoietic Cell
19%
Hematopoietic Stem Cell Transplantation
17%
Imatinib
7%
Immunosuppressive Treatment
6%
Immunotherapy
8%
In Vitro
8%
Infection
8%
Interferon
9%
Leukemia
51%
Lymphocyte
15%
Lymphocyte Transfusion
12%
Myelodysplastic Syndrome
23%
Overall Survival
13%
Platelet
6%
Reduced Intensity Conditioning
9%
Stem Cell
12%
Stem Cell Therapy
19%
T Cell
35%
Tumor Necrosis Factor
6%
Vein Occlusion
8%
Whole Body Radiation
10%
Immunology and Microbiology
Acute Graft Versus Host Disease
19%
Adoptive Immunotherapy
9%
Allogeneic Bone Marrow Transplantation
15%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Allogeneic Stem Cell Transplantation
31%
Allograft
9%
Anti-Thymocyte Globulin
10%
B Cell
11%
Blood Level
5%
Bone Marrow Cell
5%
Bone Marrow Transplantation
50%
Canis
20%
CD34
7%
Cell Transplantation
6%
Chronic Graft Versus Host Disease
13%
Ciclosporin
7%
Conditioning
30%
Cyclophosphamide
10%
Cytokine
6%
Dendritic Cell
19%
Drug Megadose
8%
Engraftment
13%
Globulin
8%
Graft-Versus-Host Disease
57%
Hematopoietic Cell
26%
Hematopoietic Stem Cell Transplantation
19%
Immunotherapy
10%
In Vitro
13%
Infection
10%
Interferon Type I
6%
Leukocyte
7%
Leukocyte Antigen
5%
Lymphocyte
25%
Methotrexate
6%
Minor Histocompatibility Antigen
5%
Myeloid
54%
Natural Killer Cell
5%
Overall Survival
14%
Peptides
6%
Platelet
8%
Stem Cell
15%
Stem Cell Transplantation
16%
T Cell
43%
Tumor Necrosis Factor
6%
Tumor Necrosis Factor Alpha
5%
